Asahi shares mark weekly slide after cyberattack halts production
ATAI Life Sciences N.V. (NASDAQ:ATAI) filed an update Monday related to its planned acquisition of Beckley Psytech Limited, a company incorporated in England and Wales. The filing, based on a press release statement, provides further information about the transaction first announced in a share purchase agreement dated June 2, 2025.
Under the agreement, ATAI Life Sciences intends to acquire all outstanding shares of Beckley Psytech not already owned by ATAI from existing shareholders. The transaction is expected to close in the fourth quarter of 2025, pending approval from ATAI shareholders and the satisfaction of customary closing conditions. The company noted that there is no assurance the transaction will be completed within this timeframe or at all.
The 8-K filing includes audited consolidated financial statements of Beckley Psytech as of December 31, 2024, and December 31, 2023, as well as for each of the three years ending December 31, 2024. It also attaches unaudited pro forma condensed combined financial information for ATAI, reflecting the potential impact of the acquisition and related transactions as of and for the six months ended June 30, 2025, and for the year ended December 31, 2024. The company stated that this financial information is presented for illustrative purposes and may not reflect the actual financial condition or results if the transaction is completed.
ATAI Life Sciences is incorporated in the Netherlands, with its common shares traded on The Nasdaq Stock Market LLC under the symbol ATAI. The company reiterated that forward-looking statements in the filing are subject to risks and uncertainties, including the possibility that the transaction may not be completed as planned.
All information is based on the company’s SEC filing made Monday.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.